HeartBeam, Inc. (BEAT) - Q3 2024 10-Q Summary
Business Context and Reporting Period
HeartBeam, Inc. is a cardiac technology company developing higher-resolution ambulatory Electrocardiogram (ECG) solutions using its proprietary Vector Electrocardiography (VECG) platform. The company is currently in the pre-revenue stage, seeking FDA clearance for its initial telehealth products. This report covers the quarterly period ended September 30, 2024.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(4.98) million | $(3.47) million | $(14.54) million | $(10.76) million |
| Operating Expenses | $5.07 million | $3.74 million | $14.94 million | $11.21 million |
| Research & Development | $2.89 million | $1.62 million | $8.17 million | $4.79 million |
| General & Administrative | $2.18 million | $2.11 million | $6.78 million | $6.42 million |
| Cash & Equivalents (End of Period) | $5.77 million | $19.18 million | $5.77 million | $19.18 million |
| Net Cash Used in Operating Activities | N/A | N/A | $(10.32) million | $(9.24) million |
| Total Liabilities | $1.86 million | $1.19 million | $1.86 million | $1.19 million |
Note: All figures in millions unless otherwise noted. No revenue was recognized in any period presented.
Material Changes vs. Prior Period
- Increased Burn Rate: Net loss for the nine months ended September 30, 2024, increased by 35% compared to the same period in 2023, driven primarily by higher R&D spending.
- R&D Expansion: R&D expenses rose 71% year-over-year for the nine-month period ($3.38 million increase), attributed to increased headcount, clinical trial costs, AI development, and stock-based compensation.
- Cash Depletion: Cash and cash equivalents decreased by approximately $10.4 million from December 31, 2023 ($16.19 million) to September 30, 2024 ($5.77 million).
- Stock-Based Compensation: Total stock-based compensation expense increased to $3.30 million for the nine months ended September 30, 2024, compared to $2.02 million in the prior year period.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt regarding the company's ability to continue as a going concern. With approximately $5.8 million in cash, the company believes existing funds are insufficient to fund operations for the next twelve months. Continued operations depend on raising additional capital.
- Regulatory Milestones: The company is in the substantive review phase of its initial 510(k) submission for a patient-held VECG device. It anticipates submitting a second 510(k) for 12-Lead ECG synthesis software following the initial clearance. No material commercial revenue is expected in 2024.
- Capital Resources: The company has an "At-The-Market" (ATM) sales agreement allowing for the sale of up to approximately $17 million of common stock. As of September 30, 2024, approximately $16.9 million remained available under this agreement.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, specifically regarding insufficient staff for segregation of duties and lack of formal risk assessment. Management concluded that disclosure controls were not effective as of September 30, 2024, though remediation efforts are underway.
- Leadership Changes: The company appointed Robert Eno as CEO and Timothy Cruickshank as CFO in late 2024 to lead the company through FDA clearance and commercialization.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $5.8 million cash balance against the current burn rate and the timeline for FDA clearance.
- Financing Availability: Assess the likelihood and terms of securing additional equity or debt financing given the "substantial doubt" disclosure.
- FDA Timeline: Monitor the status of the 510(k) submissions and the potential for delays in regulatory approval.
- Internal Controls: Review the progress of remediation efforts for the identified material weaknesses in financial reporting.
- ATM Utilization: Track the utilization of the remaining $16.9 million ATM facility and the impact of potential dilution on existing shareholders.